drugset / Trial / NCT06144697

A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy Participants

NCT06144697

Phase 1 Terminated 267 enrolled Bristol-Myers Squibb
RandomizedSequentialQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate safety, tolerability, drug and food effects on relative bioavailability of BMS-986465 and its active derivative BMS-986464 in healthy participants and healthy participants of Japanese ethnicity.

Timeline

Start
2024-01-29
Primary completion
2024-10-16
Completion
2024-10-16

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-986465 Unknown
Subject Peginterferon alfa-2a Protein / enzyme biologic
Background Famotidine Other / unclassified

Indications

No indication recorded.